Madrigal Pharmaceuticals Inc

In a Stage 2 advancing environment with supporting LT and MT uptrends and a recent momentum breakout, the structure remains bullish. However, price is extended above rising EMAs and extreme overbought on RSI and options metrics, so execution is deferred into pullbacks around the confluence of the 9/21 EMAs rather than chasing the current stretch.

• ↑ResDifera net sales $1.1B+ last 12 months; Q1 sales $311M (+127% YoY).
• ↑Active patients 42,250, +150% YoY, indicating strong adoption momentum.
• ↓Q1 2026 operating loss $94.4M vs $73.2M prior year, widening margin strain.